MARKET

MIST

MIST

Milestone Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.440
+0.280
+8.86%
Pre Market: 3.580 +0.14 +4.07% 06:42 06/02 EDT
OPEN
3.240
PREV CLOSE
3.160
HIGH
3.440
LOW
3.150
VOLUME
665.22K
TURNOVER
--
52 WEEK HIGH
27.95
52 WEEK LOW
1.690
MARKET CAP
84.48M
P/E (TTM)
-1.4357
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MIST stock price target is 4.000 with a high estimate of 6.00 and a low estimate of 3.000.

EPS

MIST News

More
Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
CNW Group · 5d ago
Backed by US and foreign investors, Canadian VC sets record at $7.263B for 2019
CNW Group · 05/20 15:00
Will Milestone Pharmaceuticals Continue to Surge Higher?
Zacks · 05/20 13:33
Top Ranked Momentum Stocks to Buy for May 19th
Zacks · 05/19 12:22
Milestone Pharmaceuticals EPS beats by $0.07
Milestone Pharmaceuticals (NASDAQ:MIST): Q1 GAAP EPS of -$0.67 beats by $0.07. Cash and cash equivalents of $102M Press Release
seekingalpha · 05/14 16:18
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
PR Newswire · 05/14 12:15
Milestone Pharmaceuticals Q1 EPS $(0.670) Up From $(17.320) YoY
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.670) per share. This is a 96.13 percent increase over losses of $(17.320) per share from the same period last year.
Benzinga · 05/14 11:24
MVIS, STML, PBI and RRD among midday movers
Seeking Alpha - Article · 05/04 16:38

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About MIST

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.
More

Webull offers kinds of Milestone Pharmaceuticals Inc stock information, including NASDAQ:MIST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIST stock news, and many more online research tools to help you make informed decisions.